LENEXA, Kan., September 4, 2025 — ELIAS Animal Health, a leader in advancing innovative therapies for veterinary oncology, today announced that it will present promising new research on its novel chemo-immunotherapy approach for canine osteosarcoma at two upcoming scientific meetings in September 2025.
- 18th American Association for Cancer Research (AACR) Conference on The Science of Cancer Health Disparities, being held September 18–21, 2025, in Baltimore, Md. The presentation will highlight the safety and efficacy of integrating traditional cytotoxic chemotherapy with a vaccine-enhanced adoptive cell therapy in canine osteosarcoma, a well-known translational model for pediatric osteosarcoma in humans.
- 2025 Veterinary Cancer Society Annual Conference, being held September 25–27, 2025, in Salt Lake City, Utah. The company’s findings will be shared in an oral presentation at the Research Spotlight Symposium on September 26, 2025. The presentation will focus on the clinical experience using this combination therapeutic strategy with its USDA-approved cancer immunotherapy known as ECI®.
ELIAS looks forward to this opportunity to highlight its work in developing cutting-edge immunotherapies and exploring the potential of combination treatment strategies to improve outcomes for canine cancer patients. The presentations will feature results from the ASCENT study which is evaluating the safety and efficacy of administering of a single dose of carboplatin followed by the ELIAS Cancer Immunotherapy (ECI®) to treat osteosarcoma, an aggressive form of bone cancer in dogs and the most common form of pediatric bone cancer in humans.
“We’re excited to bring forward data that not only advances veterinary cancer care but also underscores the broad applicability of our platform and our commitment to advancing treatments for both animal and human oncology,” said Tammie Wahaus, CEO of ELIAS Animal Health. “Presenting at these important scientific conferences demonstrates the incredible value of comparative oncology and its potential to drive innovation in cancer treatment across species.”
AACR Presentation Details:
Title: C065 Vaccine-enhanced adoptive cell therapy combined with one dose of platinum-based chemotherapy improves survival outcomes compared to standard of care 4-dose carboplatin in companion dogs with osteosarcoma
Presenting Author: Jeffrey N Bryan, DVM, MS, PhD, DACVIM(Oncology), Professor of Oncology, College of Veterinary Medicine, University of Missouri
Session: Poster Session C
Date/Time: Saturday, September 20, 6:15-7:45 p.m. ET in Baltimore, Maryland
VCS Presentation Details:
Title: One-dose carboplatin followed by vaccine-enhanced adoptive cell therapy (ECI®) improves outcomes compared to four-dose carboplatin in dogs with osteosarcoma
Presenting Author: Jeffrey N Bryan, DVM, MS, PhD, DACVIM(Oncology), Professor of Oncology, College of Veterinary Medicine, University of Missouri
Session: Spotlight Research Session
Date/Time/Location: Friday, September 26, 10:00-10:25 a.m. MT (12:00 – 12:25 p.m. ET) in Salt Lake City, Utah
For more information about ELIAS Animal Health and its innovative approach to veterinary oncology, visit www.eliasanimalhealth.com.
About ELIAS Animal Health
ELIAS Animal Health is a medical biotechnology company focused on advancing a pipeline of immunotherapies, including an adoptive cell therapy and an oncolytic virotherapy, for the treatment of canine cancers. The company’s therapeutic pipeline offers the prospect of improved clinical outcomes and the potential for fundamentally changing the way cancer is treated. Learn more at www.eliasanimalhealth.com.
About ECI®
ECI® is an autologous prescription product (USDA Product Code 95A7.50) that has been evaluated in multiple clinical studies and is approved for veterinary use by the USDA Center for Veterinary Biologics. As an adoptive cell therapy, ECI® combines an autologous vaccine with cell therapy to target a patient’s unique cancer cells. This personalized approach can improve clinical outcomes and provide a better quality of life for canine patients. ECI® is available at more than 100 authorized treatment centers across the U.S. Learn more at www.eliasanimalhealth.com/elias-cancer-immunotherapy/.